Спазмолитики в терапии абдоминального синдрома при СРК и СРК-подобном синдроме в современной клинической практике

В представленном обзоре дана оценка эффективности различных спазмолитиков в терапии абдоминальной боли при синдроме раздраженного кишечника (СРК) и СРК-подобном синдроме. На основании проведенного исследования сделан вывод о наиболее значимой эффективности миотропных спазмолитиков, и в частности, мебеверина в терапии болевого синдрома и других клинических проявлений СРК и СРК-подобного синдрома и отсутствии существенных нежелательных событий вне зависимости от продолжительности проводимой терапии.

1. Маев И. В., Осадчук М. А., Осадчук А. М. Синдром раздраженного кишечника в современной клинической практике. Терапия. 2024. Т. 10. № 3 (75). С. 116–124.

2. Осадчук М. А., Липатова Т. Е., Тюльтяева Л. А., Миронова Е. Д. Колопроктология. Руководство для врачей / Москва, ГЭОТАР-Медиа, 2024.– 336 с.

3. Осадчук А. М., Лоранская И. Д., Осадчук М. А. СРК-по синдромы в клинике внутренних болезней: современное состояние проблемы. Медицинский алфавит. 2021. № 6. С. 36–40.

4. Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome-A Systematic Review J. Clin Med. 2022 Feb 17;11(4):1044. doi: 10.3390/jcm11041044.

5. Altobelli E, Del Negro V, Angeletti PM, Latella G: Low-FODMAP diet improves irritable bowel syndrome symptoms: A meta-analysis. Nutrients. 2017, 9:10.3390/nu9090940

6. Ford AC, Sperber AD, Corsetti M, et al. Irritable bowel syndrome. Lancet 2020;396:1675–88.

7. Zheng L, Lai Y, Lu W, et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Clin Gastroenterol Hepatol 2015;13:1285–92.6

8. Darren M Brenner, Brian E Lacy. Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options. Am J Gastroenterol 2021 Aug 1;116(8):1587–1600.

9. Sara Traserra, Claudia Barber, Luis Gerardo Alcalá-González, Stefania Landolfi, Robert Lange, Carolina Malagelada, Maura Corsetti, Marcel Jimenez. Evaluation of the mechanism of action of paracetamol, drotaverine, and peppermint oil and their effects in combination with hyoscine butylbromide on colonic motility: human ex-vivo study. Front Pharmacol. 2024 Jul 10:15:1384070. doi: 10.3389/fphar.2024.1384070. eCollection 2024.

10. Muller-Lissner, S., Andresen, V., Corsetti, M., Bustos Fernandez, L., Forestier, S., Pace, F., et al. (2022). Functional abdominal cramping pain: expert practical guidance. J. Clin. Gastroenterol. 56 (10), 844–852. doi:10.1097/MCG.0000000000001764

11. Tobin G, Giglio D, Lundgren O. Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol 2009;60:3–21.

12. Centonze V, Imbimbo BP, Campanozzi F, et al. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. Am J Gastroenterol 1988;83:1262–6.

13. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 2004;10:3561–8.

14. Den Hertog A, Van den Akker J. Modification of alpha 1-receptor-operated channels by mebeverine in smooth muscle cells of Guinea-pig taenia caeci. Eur J Pharmacol 1987;138:367–74.

15. Annaházi, A.; Róka, R.; Rosztóczy, A.; Wittmann, T. Role of antispasmodics in the treatment of irritable bowel syndrome. World J. Gastroenterol. 2014, 20, 6031–6043

16. Chey, W.D.; Kurlander, J.; Eswaran, S. Irritable bowel syndrome: A clinical review. JAMA 2015, 313, 949–958.

17. Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features and Rome IV. Gastroenterology 2016;150:1262–79.

18. Moayyedi, P.; Andrews, C.N.; MacQueen, G.; Korownyk, C.; Marsiglio, M.; Graff, L.; Kvern, B.; Lazarescu, A.; Liu, L.; Paterson, W.G.; et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J. Can. Assoc. Gastroenterol. 2019, 2, 6–29.

19. Pietrzak, A.; Skrzydło-Radomańska, B.; Mulak, A.; Lipiński, M.; Małecka-Panas, E.; Regula, J.; Rydzewska, G. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz. Gastroenterol. 2018, 13, 259–288.

20. Jailwala, J.; Imperiale, T.F.; Kroenke, K. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials. Ann. Intern. Med. 2000, 133, 136–147.

21. Poynard, T.; Naveau, S.; Mory, B.; Chaput, J. C. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharm. 1994, 8, 499–510

22. Darvish-Damavandi, M.; Nikfar, S.; Abdollahi, M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J. Gastroenterol. 2010, 16, 547–553

23. El-Haggar SM, Hegazy SK, Abd-Elsalam SM, Bahaa MM. Pentoxifylline, a nonselective phosphodiesterase inhibitor, in adjunctive therapy in patients with irritable bowel syndrome treated with mebeverine.Biomed Pharmacother. 2022 Jan;145:112399. doi: 10.1016/j.biopha.2021.112399.

24. Poynard, T.; Regimbeau, C.; Benhamou, Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharm. 2001, 15, 355–361.

25. Gralnek, I.M.; Hays, R.D.; Kilbourne, A.; Naliboff, B.; Mayer, E. A. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000, 119, 654–660.

26. Hou, X.; Chen, S.; Zhang, Y.; Sha, W.; Yu, X.; El Sawah, H.; Afifi, A.F.; El-Khayat, H.R.; Nouh, A.; Hassan, M.F.; et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin. Drug Investig. 2014, 34, 783–793

27. Dwaipayan Sarathi Chakraborty, Avijit Hazra, Amrita Sil, Shantasil Pain. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? J Family Med Prim Care. 2019 Oct 31;8(10):3173–3178. doi: 10.4103/jfmpc.jfmpc_522_19. eCollection 2019 Oct.

28. Kruis W, Weinzierl M, Schüssler P, et al. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 1986;34:196–201.

29. Everitt H, Moss-Morris R, Sibelli A, et al. Management of irritable bowel syndrome in primary care: The results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterol 2013;13:68.

30. 26. Darvish-Damavandi, M.; Nikfar, S.; Abdollahi, M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J. Gastroenterol. 2010, 16, 547–553

31. Lee, K.J.; Kim, N.Y.; Kwon, J.K.; Huh, K.C.; Lee, O.Y.; Lee, J.S.; Choi, S.C.; Sohn, C.I.; Myung, S.J.; Park, H.; et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: A multicenter, randomized clinical trial, compared with mebeverine. J. Neurogastroenterol. Motil. 2011, 23, 1098–1104

32. Lee, K.J.; Poong-Lyul, R. A Randomized, Open Labeled, Multicenter Clinical Trial on the Effectiveness and Safety of the 5-HT3-Receptor Antagonist Ramosetron in Male Patients with Irritable Bowel Syndrome With Diarrhea: Comparison With Mebeverine. Gastroenterology 2011, 140, S-06

33. Jones, R.H.; Holtmann, G.; Rodrigo, L.; Ehsanullah, R.S.; Crompton, P.M.; Jacques, L.A.; Mills, J. G. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment. Pharm. 1999, 13, 1419–1427

34. Friedel D, Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology. 2001;120(2):557–60.